Evidence map›Paper›PMID 39012710›Full record

ArticleJCI insight2024

Targeting CEBPA to restore cellular identity and tissue homeostasis in pulmonary fibrosis.

Qi Tan, Jack H Wellmerling, Shengren Song, Sara R Dresler, Jeffrey A Meridew, Kyoung M Choi, Yong Li, Y S Prakash, Daniel J Tschumperlin

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Mechanosensing Pathways in the Progression of Pulmonary Fibrosis.Current opinion in biomedical engineering · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qi TanThe Hormel Institute, University of Minnesota, Austin, Minnesota, USA.
Jack H WellmerlingDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Shengren SongThe Hormel Institute, University of Minnesota, Austin, Minnesota, USA.
Sara R DreslerDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Jeffrey A MeridewDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Kyoung M ChoiDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Yong LiDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Y S PrakashDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Daniel J TschumperlinDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.

Funding

Mechanobiology of Lung FibrosisR01HL092961 · NHLBI · MAYO CLINIC ROCHESTER · PI Daniel J. Tschumperlin · 2009 to 2026
$8.0M
Interdisciplinary Training in Lung Physiology and Biomedical EngineeringT32HL105355 · NHLBI · MAYO CLINIC ROCHESTER · PI PRAKASH, Y. S., SIECK, GARY C. · 2012 to 2021
$3.9M
Targeting CEBPA To Restore Epithelial-Mesenchymal Homeostasis In Lung FibrosisR01HL153026 · NHLBI · UNIVERSITY OF MINNESOTA · PI TAN, QI · 2020 to 2024
$2.3M
NHLBI NIH HHS R01 HL092961NHLBI NIH HHS R01 HL153026NHLBI NIH HHS T32 HL105355
6 · The paper itself

Abstract

Fibrosis in the lung is thought to be driven by epithelial cell dysfunction and aberrant cell-cell interactions. Unveiling the molecular mechanisms of cellular plasticity and cell-cell interactions is imperative to elucidating lung regenerative capacity and aberrant repair in pulmonary fibrosis. By mining publicly available RNA-Seq data sets, we identified loss of CCAAT enhancer-binding protein alpha (CEBPA) as a candidate contributor to idiopathic pulmonary fibrosis (IPF). We used conditional KO mice, scRNA-Seq, lung organoids, small-molecule inhibition, and potentially novel gene manipulation methods to investigate the role of CEBPA in lung fibrosis and repair. Long-term (6 months or more) of Cebpa loss in AT2 cells caused spontaneous fibrosis and increased susceptibility to bleomycin-induced fibrosis. Cebpa knockout (KO) in these mice significantly decreased AT2 cell numbers in the lung and reduced expression of surfactant homeostasis genes, while increasing inflammatory cell recruitment as well as upregulating S100a8/a9 in AT2 cells. In vivo treatment with an S100A8/A9 inhibitor alleviated experimental lung fibrosis. Restoring CEBPA expression in lung organoids ex vivo and during experimental lung fibrosis in vivo rescued CEBPA deficiency-mediated phenotypes. Our study establishes a direct mechanistic link between CEBPA repression, impaired AT2 cell identity, disrupted tissue homeostasis, and lung fibrosis.

Indexed as

BleomycinCCAAT-Enhancer-Binding ProteinsHomeostasisMice, KnockoutAlveolar Epithelial CellsAnimalsDisease Models, AnimalHumansIdiopathic Pulmonary FibrosisLungMaleMiceOrganoidsPulmonary FibrosisBleomycinCCAAT-Enhancer-Binding ProteinsCEBPA protein, mouseAdult stem cellsFibrosisPulmonary surfactantsPulmonologyStem cells

Identifiers

PMID39012710
PMCPMC11343593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.